PHVS PHVS
Company Profile ↓Company Overview
PHVS (PHVS) is a publicly traded company listed on with a market capitalization of $2.18B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +57.38% |
| 6 Months: | +20.17% |
| 3 Months: | +11.33% |
| 1 Month: | -3.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 42.19M | 40.37M | 39.66M | 47.60M | 44.27M |
| Operating Income | - | -42.19M | -40.37M | -39.66M | -47.60M | -44.27M |
| EBITDA | - | -42.08M | -40.27M | -39.56M | -47.49M | -44.17M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -46.04M | -45.28M | -37.32M | -45.08M | -38.93M |
| Tax Provision | - | 302.67K | 202.78K | -181.47K | 1.66M | 273.11K |
| Net Income | - | -46.34M | -45.48M | -37.14M | -46.74M | -39.20M |
| Diluted EPS | - | -0.85 | -0.83 | -0.60 | - | -0.60 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 86.71M | 96.91M | 145.69M | 169.82M |
| Operating Income | - | -86.71M | -96.91M | -145.69M | -169.82M |
| EBITDA | - | -86.56M | -96.66M | -145.42M | -169.40M |
| Interest Expense | 267.51K | 16.11K | - | - | - |
| Pretax Income | - | -75.65M | -99.83M | -132.40M | -173.71M |
| Tax Provision | - | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | - | -76.33M | -100.88M | -134.22M | -175.70M |
| Diluted EPS | - | -2.27 | -2.63 | -2.48 | -2.97 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 167.73M | 398.69M | 291.37M | 301.45M |
| Current Assets | - | 166.85M | 397.85M | 289.42M | 299.17M |
| Cash & Equivalents | - | 161.84M | 391.23M | 280.73M | 291.68M |
| Inventory | - | - | - | - | - |
| Receivables | 8.45K | 0 | - | - | - |
| Total Liabilities | - | 18.47M | 14.65M | 23.61M | 30.18M |
| Current Liabilities | - | 18.22M | 14.60M | 22.97M | 29.60M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 436.82K | 238.91K | 861.47K | 776.80K |
| Total Equity | - | 149.26M | 384.05M | 267.76M | 271.27M |
| Shares Outstanding | - | 33.82M | 52.29M | 54.38M | 65.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -67.16M | -93.05M | -120.13M | -137.07M |
| Investing Cash Flow | - | -124.30K | -89.98K | -538.09K | -164.62K |
| Financing Cash Flow | - | 8.65M | 325.39M | 2.68M | 160.61M |
| Capital Expenditure | - | -124.30K | -89.98K | -538.09K | -164.62K |
| Free Cash Flow | - | -67.29M | -93.14M | -120.67M | -137.24M |
| Net Change in Cash | - | -58.64M | 232.25M | -117.99M | 23.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -51.1% | -26.3% | -50.1% | -64.8% |
| ROCE % | - | -58.0% | -25.2% | -54.3% | -62.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHVS
Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run
Pharvaris stock has delivered a strong 103.0% return over the past five years, yet the latest valuation checks and market multiples suggest the shares may now sit on the expensive side rather than offering clear value. Over the last 5 years…
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will…
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a therap…
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
PHVS — Frequently Asked Questions
What is the current share price of PHVS?
As of 2026-08-05 17:25 PDT, PHVS trades at $33.42 on NASDAQ/NYSE. Its 52-week range is $20.12 to $35.96.
What is the market capitalisation of PHVS?
PHVS has a market capitalisation of $2.18B on NASDAQ/NYSE.
What is the P/E ratio of PHVS?
PHVS trades at a trailing price-to-earnings (P/E) ratio of -11.25. Its price-to-book (P/B) ratio is 8.03.
What is the return on equity (ROE) of PHVS?
PHVS has a return on equity (ROE) of -64.77%. Its return on capital employed (ROCE) is -62.47%.
Is PHVS a good stock to buy?
This page provides a data-driven analysis of PHVS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.